Immunogenicity of a recombinant pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster

Bucher, Brigitte; Francioli, P.; Geudelin, B.; Fritzell, Bernard; Lavanchy, Daniel; Frei, P. C.

doi:10.1007/bf01974539

Cited by 14 publications

(8 citation statements)

References 24 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The administration of both hyperimmunglobulin and HBV vaccine during the initial chemotherapy period might be a solution for the early development of HBV infection. Bucher et al reported that Gen Hevac B also induced an earlier response than other vaccines [11]. Similarly, in 41 vaccine recipients in the Gen Hevac B group, the antibody response after ® rst vaccine dose was 47%, whereas it was only 32% in other group in our study.…”

Section: Discussionsupporting

confidence: 58%

THE COMPARISON OF ANTIBODY RESPONSE TO DIFFERENT HEPATITIS B VACCINES WITH AND WITHOUT pre-S2 ANTIGEN IN CHILDREN WITH CANCER

Emir

Büyükpamukçu

Akyüz

et al. 2002

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

Children with cancer are at an increased risk of hepatitis B infection and chronic liver disease. Since hepatitis B vaccines containing pre-S2 antigen has been recently reported as being more efficient in providing immunization in healthy individuals, the authors compared antibody response to pre-S2-containing vaccine with no-pre-S2-containing hepatitis B vaccine, when given in double doses to 100 children receiving chemotherapy. Patients, aged 1 to 16 years with negative HBV serology, were vaccinated with 2 different types of HBV vaccines between 1997 and 1999. Group 1 received Gen Hevac B containing pre-S2 (n = 41) in a dose of 20 microg for patients younger than 10 years old and 40 microg for older patients. Group 2 was vaccinated at the same dose with hepatitis B vaccines not containing pre-S2 antigen. All vaccinations were repeated at 0, 1, and 6 months. Serum samples were drawn for determination of anti-HBs titers at 1, 3, 6, and 8 months. After the third dose of vaccine, the seroconversion rate was 72% in group 1 and 62% in group 2. The anti-HBs levels were higher in the group receiving pre-S2-containing hepatitis B vaccine. However, the difference between groups was not statistically significant (p > .05). The administration of pre-S2-containing hepatitis B vaccines may give a better seroconversion and higher antibody response to vaccination in children with cancer. But a further large-scale study is needed to confirm this finding.

show abstract

Section: Discussionsupporting

confidence: 58%

THE COMPARISON OF ANTIBODY RESPONSE TO DIFFERENT HEPATITIS B VACCINES WITH AND WITHOUT pre-S2 ANTIGEN IN CHILDREN WITH CANCER

Emir

Büyükpamukçu

Akyüz

et al. 2002

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

show abstract

“…The 299 subjects were hospital employees included in a vaccination study [2]. A second group of 360 samples obtained from 308 vaccinated subjects (hospital employees, police ocers and travelers), all of whom were also without anti-HBs detectable by a commercial EIA, consisted of: · 118 samples from 118 nonresponders (74 men and 44 women, aged 25±63 years, median 43 years), of whom 36 were after primovaccination and 82 were after primovaccination and revaccination.…”

Section: Serum Samplesmentioning

confidence: 99%

Absence of anti-hepatitis B surface antibody after vaccination does not necessarily mean absence of immune response

Greub

Zysset

Genton

et al. 2001

Medical Microbiology and Immunology

View full text Add to dashboard Cite

A small number of subjects vaccinated against hepatitis B do not produce anti-hepatitis B surface (HBs) antibody levels detectable by commercial assays. Others lose detectable anti-HBs at some time after vaccination. The absence of clinical hepatitis despite potential exposure to hepatitis B virus (HBV) in both kinds of subjects suggests that they might be protected by low antibody levels. However, besides anti-HBs, T helper response and memory cells which may be induced by the vaccine are certainly also important for immunity against HBV. In the present study, samples from vaccinated subjects, found to be anti-HBs negative in an initial assay, subsequently showed positive results in, respectively, 25%, 36% and 38% of the cases, when a second, third and fourth assay was used. In addition, 360 samples from "nonresponders" and from vaccinees who had lost anti-HBs, the reactivity of which was under the enzyme-linked immunoassay-cut-off value were compared to that of nonvaccinated controls. The absorbances were found to be significantly higher in the nonresponders (0.038) and in the vaccinees having lost anti-HBs (0.041), than in the controls (0.025). Such findings contribute to explaining why so-called nonresponders as well as vaccinees who have lost anti-HBs nevertheless appear to be protected.

show abstract

“…In addition to single-antigen VLPs containing only HBsAg S protein, multi-antigen VLP vaccines, containing either HBsAg M and S (pre-S 2 /S domains) or HBsAg M, L and S proteins (pre-S 1 /pre-S 2 /S domains), have been produced in CHO cells and were demonstrated to be safe and immunogenic in neonates [21,283,284]. Due to the presence of broader-range HBsAg epitopes, these vaccines were believed to be more immunogenic and fast acting and to provide better protection compared with VLP vaccines containing HBsAg S protein alone [285,286]. Two such vaccines, GenHevac B ® and Sci-B-Vac ® (formerly, Bio-Hep-B TM ), developed in France and Israel, respectively, are on the market (Table 2).…”

Section: Mammalian and Avian Cellsmentioning

confidence: 99%

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development

Kushnir

Streatfield

Yusibov

2012

Vaccine

523

403

View full text Add to dashboard Cite

Virus-like particles (VLPs) are a class of subunit vaccines that differentiate themselves from soluble recombinant antigens by stronger protective immunogenicity associated with the VLP structure. Like parental viruses, VLPs can be either non-enveloped or enveloped, and they can form following expression of one or several viral structural proteins in a recombinant heterologous system. Depending on the complexity of the VLP, it can be produced in either a prokaryotic or eukaryotic expression system using target-encoding recombinant vectors, or in some cases can be assembled in cell-free conditions. To date, a wide variety of VLP-based candidate vaccines targeting various viral, bacterial, parasitic and fungal pathogens, as well as non-infectious diseases, have been produced in different expression systems. Some VLPs have entered clinical development and a few have been licensed and commercialized. This article reviews VLP-based vaccines produced in different systems, their immunogenicity in animal models and their status in clinical development.

show abstract

Immunogenicity of a recombinant pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster

Cited by 14 publications

References 24 publications

THE COMPARISON OF ANTIBODY RESPONSE TO DIFFERENT HEPATITIS B VACCINES WITH AND WITHOUT pre-S2 ANTIGEN IN CHILDREN WITH CANCER

THE COMPARISON OF ANTIBODY RESPONSE TO DIFFERENT HEPATITIS B VACCINES WITH AND WITHOUT pre-S2 ANTIGEN IN CHILDREN WITH CANCER

Absence of anti-hepatitis B surface antibody after vaccination does not necessarily mean absence of immune response

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development

Contact Info

Product

Resources

About